Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease
Sirolimus is used to treat pediatric patients with PIK3CD mutation-related immunodeficiency disease. However, the initial dosages of sirolimus remain undecided. The present study aims to explore initial dosages in pediatric patients with PIK3CD mutation-related immunodeficiency disease. Pediatric pa...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.919487/full |
| _version_ | 1811261120561807360 |
|---|---|
| author | Xiao Chen Jinglin Wang Jianger Lan Xilin Ge Hong Xu Yu Zhang Zhiping Li |
| author_facet | Xiao Chen Jinglin Wang Jianger Lan Xilin Ge Hong Xu Yu Zhang Zhiping Li |
| author_sort | Xiao Chen |
| collection | DOAJ |
| description | Sirolimus is used to treat pediatric patients with PIK3CD mutation-related immunodeficiency disease. However, the initial dosages of sirolimus remain undecided. The present study aims to explore initial dosages in pediatric patients with PIK3CD mutation-related immunodeficiency disease. Pediatric patients with this disease were analyzed using the population pharmacokinetic (PPK) model and the Monte Carlo simulation. Body weight and concomitant use of posaconazole were included in the final PPK model, where, under the same weight, clearances of sirolimus were 1 : 0.238 between children without and children with posaconazole. Without posaconazole, the initial dosages of sirolimus were 0.07, 0.06, 0.05, and 0.04 mg/kg/day for body weights of 10–14, 14–25, 25–50, and 50–60 kg, respectively. With posaconazole, the initial dosages of sirolimus were 0.02 mg/kg/day for body weights of 10–60 kg. This is the first attempt to build a sirolimus PPK model for recommending initial dosages in children with PIK3CD mutation-related immunodeficiency disease, thereby providing a reference for individualized clinical drug administration. |
| first_indexed | 2024-04-12T18:57:41Z |
| format | Article |
| id | doaj.art-79182462bdb84b0785751875fd3595a4 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T18:57:41Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-79182462bdb84b0785751875fd3595a42022-12-22T03:20:16ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-09-011310.3389/fphar.2022.919487919487Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency diseaseXiao Chen0Jinglin Wang1Jianger Lan2Xilin Ge3Hong Xu4Yu Zhang5Zhiping Li6Department of Pharmacy, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, ChinaDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Pharmacy, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, ChinaDepartment of Pharmacy, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, ChinaDepartment of Nephrology, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, ChinaDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Pharmacy, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, ChinaSirolimus is used to treat pediatric patients with PIK3CD mutation-related immunodeficiency disease. However, the initial dosages of sirolimus remain undecided. The present study aims to explore initial dosages in pediatric patients with PIK3CD mutation-related immunodeficiency disease. Pediatric patients with this disease were analyzed using the population pharmacokinetic (PPK) model and the Monte Carlo simulation. Body weight and concomitant use of posaconazole were included in the final PPK model, where, under the same weight, clearances of sirolimus were 1 : 0.238 between children without and children with posaconazole. Without posaconazole, the initial dosages of sirolimus were 0.07, 0.06, 0.05, and 0.04 mg/kg/day for body weights of 10–14, 14–25, 25–50, and 50–60 kg, respectively. With posaconazole, the initial dosages of sirolimus were 0.02 mg/kg/day for body weights of 10–60 kg. This is the first attempt to build a sirolimus PPK model for recommending initial dosages in children with PIK3CD mutation-related immunodeficiency disease, thereby providing a reference for individualized clinical drug administration.https://www.frontiersin.org/articles/10.3389/fphar.2022.919487/fullsirolimusPIK3CD mutationimmunodeficiency diseaseinitial dosages recommendationpediatric patients |
| spellingShingle | Xiao Chen Jinglin Wang Jianger Lan Xilin Ge Hong Xu Yu Zhang Zhiping Li Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease Frontiers in Pharmacology sirolimus PIK3CD mutation immunodeficiency disease initial dosages recommendation pediatric patients |
| title | Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease |
| title_full | Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease |
| title_fullStr | Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease |
| title_full_unstemmed | Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease |
| title_short | Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease |
| title_sort | initial sirolimus dosage recommendations for pediatric patients with pik3cd mutation related immunodeficiency disease |
| topic | sirolimus PIK3CD mutation immunodeficiency disease initial dosages recommendation pediatric patients |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.919487/full |
| work_keys_str_mv | AT xiaochen initialsirolimusdosagerecommendationsforpediatricpatientswithpik3cdmutationrelatedimmunodeficiencydisease AT jinglinwang initialsirolimusdosagerecommendationsforpediatricpatientswithpik3cdmutationrelatedimmunodeficiencydisease AT jiangerlan initialsirolimusdosagerecommendationsforpediatricpatientswithpik3cdmutationrelatedimmunodeficiencydisease AT xilinge initialsirolimusdosagerecommendationsforpediatricpatientswithpik3cdmutationrelatedimmunodeficiencydisease AT hongxu initialsirolimusdosagerecommendationsforpediatricpatientswithpik3cdmutationrelatedimmunodeficiencydisease AT yuzhang initialsirolimusdosagerecommendationsforpediatricpatientswithpik3cdmutationrelatedimmunodeficiencydisease AT zhipingli initialsirolimusdosagerecommendationsforpediatricpatientswithpik3cdmutationrelatedimmunodeficiencydisease |